Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. - Wikidata - awgldk - TriplyDB

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

http://www.wikidata.org/entity/Q45211867

about

Osteoclasts are active in bone forming metastases of prostate cancer patients Denosumab The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements Bone metastases: When and how lung cancer interacts with bone Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.The role of miRNAs in bone metastasis and their significance in the detection of bone metastasis: a review of the published data.Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling.An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.Targeted treatments of bone metastases in patients with lung cancer Recent developments in bisphosphonates for patients with metastatic breast cancer.Risk factors for bone metastasis in patients with primary lung cancer: study protocol for a systematic review.Evolving role of bone biomarkers in castration-resistant prostate cancer.Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.Functional protease profiling for diagnosis of malignant disease.Treatment and prevention of bone complications from prostate cancer.Metastatic tumors to the jaws and mouth.Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer.Targeted therapy in prostate cancer.Incidence and outcome of bone metastatic disease at University Malaya Medical Centre Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond.Contemporary therapeutic approaches targeting bone complications in prostate cancer Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats.Bone remodeling markers and bone metastases: From cancer research to clinical implications Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

P2860

Q21090081-FF8A8831-BE1D-4564-97F8-32E5FE5C7EFC Q24651938-864629A3-53AB-4276-B2F4-4DBAB377FE9F Q26750672-A56C9BE6-6055-41B1-B826-4F1019BD790C Q26823287-D7ED247C-D0DB-4750-BDBB-08BDC5B79681 Q27021268-6385ECC9-B84C-45F1-858B-DECFF4F58F5B Q28076646-03848C9F-7DCA-4DBE-8DE1-1F6F97ED12BD Q30438167-4FD7E271-469C-4815-AC5F-F8BF6723FE57 Q30684593-5BB62933-EC72-4139-BB2D-0849D0B21838 Q30883662-BAD7C8F5-56D4-42E6-8D87-7CAFA378FB8F Q33347582-248D3A6E-D99C-443F-9933-CEA2989E9515 Q33441667-15B5F382-59D8-4B64-8B11-5817E9474435 Q33491284-111DB8B6-DDFE-4AF5-92DB-6CEDA3CBAA89 Q33602302-C4741196-F045-4830-BCD2-B0AFA42A2AA5 Q33620502-D4334B69-E3FC-4C38-A9DA-8E3C41A04007 Q33727640-E1CAC88E-560F-40DA-B59E-D575161FC10E Q33759713-49D01CAA-3012-44E5-B45F-D2DE603FEF42 Q33935632-A3C9108B-835B-4EE5-A208-7E7A784EA430 Q33996458-D41BCAE6-BA01-4C71-B605-9887DE36C778 Q34023877-15989ABA-3823-44BE-B7F2-E2A1B53B56A9 Q34026943-1A5E52C7-B028-4AE8-BE6D-54E2BFB6710A Q34032678-CF3F5E11-B1CE-43DE-BA2A-880B0587D946 Q34041808-50CC0A7D-3FC5-44F7-8B83-1D0FB94C4D85 Q34116114-BB8386B9-523D-421D-A92F-A924B2421E27 Q34441944-A4ACA1EA-E886-4A27-9EB4-E6DE5A18F45B Q34577367-422406D7-BF70-4F25-BF52-4002F89F9DFB Q34613941-B16A4CFD-8E8B-4344-812D-482A880714AC Q34617864-6C6AAF87-20EC-4531-B10B-AB2E90D85422 Q34627984-1FF30811-EFA7-4291-9EB3-90271A658023 Q34629549-064AC846-406D-46E6-B1A6-79F3F6481097 Q34634763-8CD8B6EF-F539-47EF-B44F-60729BA771FE Q34952485-87FE7AC5-5AC2-43A1-97A9-F4CCD43004DC Q34960635-6DB78087-C816-4077-9FCC-06D330DF8386 Q34960778-C5A7D484-B997-45FD-8B4D-5F7B0BE91730 Q34960867-1EFBD582-0690-4281-88CE-A0C19DA2C112 Q35022212-28BA1998-E949-4663-A93A-D7BB37E65C3D Q35051643-8C98DDC6-2520-4439-89B1-2E4886664D94 Q35053491-E2B64D76-FEEC-456C-83E2-60261BB5C2D9 Q35211934-DBBAD96A-69DB-4FFF-95D8-9CD72B170EF7 Q35531006-5B8EC0FD-46AB-4085-94BE-0FD54D0B4C80 Q35569309-DF482A6A-8295-45E2-85E5-C9BF762DA5D2

P2860

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.

http://www.wikidata.org/entity/Q45211867

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Bone turnover markers as predi ...... ancer, and other solid tumors.

@en

Bone turnover markers as predi ...... ancer, and other solid tumors.

@nl

type

label

Bone turnover markers as predi ...... ancer, and other solid tumors.

@en

Bone turnover markers as predi ...... ancer, and other solid tumors.

@nl

prefLabel

Bone turnover markers as predi ...... ancer, and other solid tumors.

@en

Bone turnover markers as predi ...... ancer, and other solid tumors.

@nl

P1433

Q45211867-EB28EC7D-01D3-4343-A12E-3CD24AFF8575

P1476

Q45211867-1656F183-4C24-48A1-8364-31A8D0C872BE

P2093

Q45211867-2FCCD47E-09EC-4E39-A676-92BC857F7F95

Q45211867-32C7A3E2-4FC6-4CF1-9DDC-CB59F6D858CC

Q45211867-33C8421C-98AD-470E-B4E2-E05C86A9E8A1

Q45211867-3F9C4272-059E-4EAF-A8F8-242DDF081341

Q45211867-77385004-3C2F-4CBC-8AF3-B5841CC5E25A

Q45211867-7A4F3DAD-EBF6-43E3-AC9A-044123A7AFB3

Q45211867-85599888-6DA9-4B91-925C-AE0F7C3175D6

Q45211867-986A1B45-3B26-4E59-92D4-52104500328E

Q45211867-CB32068C-B52F-461B-914C-51A8628CD6A2

Q45211867-DE75B9C3-2DC4-435D-8419-B3A657FD56FD

P304

Q45211867-E143ED42-258A-42F6-B833-13F22AB451A3

P31

Q45211867-90255DF6-4ABD-4108-BD6F-31CAF8715346

P356

Q45211867-9762FA67-1637-4BDA-8640-E19B4063CAA6

P407

Q45211867-B6352510-9C7C-4CB0-891E-FCA0D213290E

P433

Q45211867-1E780D3E-1CE0-4096-904E-69772FCF6F11

P478

Q45211867-5799F8D5-7221-46E3-955F-91A050D4CFA7

P577

Q45211867-0677023B-FF7D-448E-BEEF-766049F3DB07

P5875

Q45211867-CCEADB05-EB3A-4DE1-AB98-24D6463B516E

P698

Q45211867-BE55AFAC-8792-4315-A1DB-E216DC64BAAB

P356

P1433

Journal of the National Cancer Institute

P1476

Bone turnover markers as predi ...... ancer, and other solid tumors.

@en

P2093

Allan Lipton

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

Janet E Brown

http://www.w3.org/2001/XMLSchema#string

Ker-Ai Lee

http://www.w3.org/2001/XMLSchema#string

Matthew Smith

http://www.w3.org/2001/XMLSchema#string

Ming Zheng

http://www.w3.org/2001/XMLSchema#string

Pierre Major

http://www.w3.org/2001/XMLSchema#string

Richard J Cook

http://www.w3.org/2001/XMLSchema#string

Robert E Coleman

http://www.w3.org/2001/XMLSchema#string

Yong-Jiang Hei

http://www.w3.org/2001/XMLSchema#string

P304

59-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJI002

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8099365

http://www.w3.org/2001/XMLSchema#string

P698

15632381

http://www.w3.org/2001/XMLSchema#string